138 related articles for article (PubMed ID: 31730591)
21. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
27. A unique and as yet unexplored subset of metastatic colorectal cancer: widespread lymph-node-only recurrence.
Lipshitz J; Astrow AB; Xu Y
J Gastrointest Cancer; 2013 Dec; 44(4):466-71. PubMed ID: 23247989
[No Abstract] [Full Text] [Related]
28. Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?
Salles G
J Clin Oncol; 2011 Sep; 29(25):3349-50. PubMed ID: 21810690
[No Abstract] [Full Text] [Related]
29. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Cavenagh J; Oakervee H; Baetiong-Caguioa P; Davies F; Gharibo M; Rabin N; Kurman M; Novak B; Shiraishi N; Nakashima D; Akinaga S; Yong K
Br J Cancer; 2017 Oct; 117(9):1295-1302. PubMed ID: 28873084
[TBL] [Abstract][Full Text] [Related]
30. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
31. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
32. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
Ehlert K; Hansjuergens I; Zinke A; Otto S; Siebert N; Henze G; Lode H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414861
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Hainsworth JD; Becker KP; Mekhail T; Chowdhary SA; Eakle JF; Wright D; Langdon RM; Yost KJ; Padula GDA; West-Osterfield K; Scarberry M; Shaifer CA; Shastry M; Burris HA; Shih K
J Neurooncol; 2019 Sep; 144(2):303-311. PubMed ID: 31392595
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors in multiple myeloma.
Pratt G
Lancet Oncol; 2013 Oct; 14(11):1038-1039. PubMed ID: 24055413
[No Abstract] [Full Text] [Related]
36. Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Mele G; Giannotta A; Pinna S; Loseto G; Coppi MR; Brocca CM; Melpignano A; Quarta G
Leuk Lymphoma; 2010 May; 51(5):937-40. PubMed ID: 20350279
[No Abstract] [Full Text] [Related]
37. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
38. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
40. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]